Compare McKesson Corporation (MCK) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs T Rowe Price Group Inc — how do they compare? McKesson Corporation trades at $832.45 (market cap $98.51B), while T Rowe Price Group Inc trades at $116.5 (market cap $25.14B). The key difference: McKesson Corporation is far larger — about 3.9× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.43%). Which is the better fit depends on your goals.
| MCK | TROW | |
|---|---|---|
Market Cap | $98.51B | $25.14B |
Sector | Health | Financials |
52-Week High | $995.69 | $120.16 |
52-Week Low | $659.01 | $86.19 |
Enterprise Value | $103.15B | $21.85B |
Dividend Yield | 0.39% | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
T. Rowe Price (TROW) trades at $116.345, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings that beat expectations, with revenue growth from $7.1B in 2024 to $7.3B in 2025 and a net income margin of 28.28%. Recent news highlights the launch of an active crypto ETF and AUM reaching $1.89 trillion in June 2026.
The outlook for TROW is mixed; valuation ratios like a P/E of 12.59 suggest potential undervaluation, but analyst consensus is cautious with a hold-heavy rating. Key risks include equity outflows and market volatility, while opportunities lie in diversified AUM growth and innovation. The stock's performance hinges on sustaining profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
